Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Imugene Limited
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04432207CT.gov A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Squamous Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Imu-201 (Pd1-Vaxx) (this asset) | Imugene Limited | P1 | CC · 43 |
| Carboplatin | zhang yi | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | Qilu Hospital of Shandong University | P4 | BBB |
| Docetaxel | Shanghai JMT-Bio Inc. | P3 | BB |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P3 | BB |
| Gefitinib | Seoul Veterans Hospital | P3 | BB |
| Etoposide | Barbara Ann Karmanos Cancer Institute | P3 | BB |
| Veliparib | AbbVie | P3 | B |
| Nivolumab | Gruppo Oncologico Italiano di Ricerca Clinica | P3 | B |
+42 more in the Squamous Cell Lung Carcinoma cohort
Other indications for Imu-201 (Pd1-Vaxx)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P1 | CC · 43 |
| Lung Adenocarcinoma | — | P1 | CC · 43 |
| Colorectal Cancer | — | P2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Imu-201 (Pd1-Vaxx) in Squamous Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/imu-201-pd1-vaxx-squamous-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →